Bildkälla: Stockfoto

Asarina Pharma: Short-term Delay in Tourette’s Study - Redeye

The initiation of Asarina Pharma’s phase IIa study in Tourette’s has been postponed until December 2021 due to an administrative backlog at public authorities.

The initiation of Asarina Pharma’s phase IIa study in Tourette’s has been postponed until December 2021 due to an administrative backlog at public authorities.
Börsvärldens nyhetsbrev
ANNONSER